1-7 of 7
Pierfranco Conte
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial

Maria Vittoria Dieci, Valentina Guarneri, Anna Tosi, Giancarlo Bisagni, Antonino Musolino, Simon Spazzapan, Gabriella Moretti, Grazia Maria Vernaci, Gaia Griguolo, Tommaso Giarratano, Loredana Urso, Francesca Schiavi, Claudia Pinato, Giovanna Magni, Marcello Lo Mele, Gian Luca De Salvo, Antonio Rosato, Pierfranco Conte
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 308–317.
https://doi.org/10.1158/1078-0432.CCR-21-2260
Published: 15 January 2022
View article titled, Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Open the PDF for Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial in another window
Includes: Supplementary data
Journal Articles

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

Patrick Neven, Stephen R.D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva-Maria Grischke, PierFranco Conte, Yi Lu, Nadine Haddad, Karla C. Hurt, Antonio Llombart-Cussac, George W. Sledge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5801–5809.
https://doi.org/10.1158/1078-0432.CCR-20-4685
Published: 01 November 2021
View article titled, MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer
Open the PDF for MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR<sup>+</sup>, HER2<sup>−</sup>-Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarneri, Javier Cortes, Patricia Villagrasa, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa A. Carey, Charles M. Perou, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3116–3125.
https://doi.org/10.1158/1078-0432.CCR-20-4102
Published: 01 June 2021
View article titled, Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy
Open the PDF for Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1582.
https://doi.org/10.1158/1078-0432.CCR-21-0193
Published: 01 March 2021
View article titled, Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer
Open the PDF for Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer in another window
Journal Articles

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Antonino Musolino, Francesco Giotta, Anita Rimanti, Ornella Garrone, Elena Bertone, Katia Cagossi, Oriana Nanni, Federico Piacentini, Enrico Orvieto, Gaia Griguolo, Matteo Curtarello, Loredana Urso, Laia Paré, Nuria Chic, Roberto D'Amico, Aleix Prat, Pierfranco Conte
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5843–5851.
https://doi.org/10.1158/1078-0432.CCR-20-1731
Published: 13 November 2020
View article titled, <em>PIK3CA</em> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Open the PDF for <em>PIK3CA</em> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (20): 5310–5319.
https://doi.org/10.1158/1078-0432.CCR-20-1764
Published: 15 October 2020
View article titled, A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab

Laura Bonanno, Angela De Paoli, Elisabetta Zulato, Giovanni Esposito, Fiorella Calabrese, Adolfo Favaretto, Antonio Santo, Alessandro Del Conte, Marco Chilosi, Francesco Oniga, Gabriella Sozzi, Massimo Moro, Francesco Ciccarese, Giorgia Nardo, Roberta Bertorelle, Cinzia Candiotto, Gian Luca De Salvo, Alberto Amadori, PierFranco Conte, Stefano Indraccolo
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3316–3324.
https://doi.org/10.1158/1078-0432.CCR-16-2410
Published: 02 July 2017
View article titled, LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
Open the PDF for LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab in another window
Includes: Supplementary data